Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aifa’s director dismissed
The dismissal of Mr Martini follows a two-year investigation in which police found evidence for fraudulent transactions in return for the falsification of clinical data required for drug
The dismissal of Mr Martini follows a two-year investigation in which police found evidence for fraudulent transactions in return for the falsification of clinical data required for drug
The draft guidance issued by the National Institute for Health and Clinical Excellence (NICE), contends that Roche’s Avastin (bevacizumab), Bayer’s Nexavar (sorafenib), Pfizer’s Sutent (sunitinib) and Wyeth’s Torisel
The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the right, subject to certain conditions, to extend the licensing agreement to
Mr Teckman was recently president and CEO of Sutura, a medical device manufacturer in Orange Country, California where he led a successful turnaround effort. Mr Teckman is a
The UK will be the first country to market Xamiol. This will take place in the fourth quarter of 2008. Prior to the approval of Xamiol, Leo Pharma
Ascension Health Ventures, National Healthcare Services and existing investors Artiman Ventures and ICCP Ventures also joined the round with strong support. Mohan Uttarwar, CEO of BioImagene, said: “This
For the past six years Mr Gonze was the COO at Unither Pharmacueticals. He has broad experience in all aspects of commercial operations having held senior level positions
Mr Hart comes to Emisphere with over 16 years of commercial experience in the pharmaceutical industry. In his most recent capacity at Organon, part of Schering Plough, he
Dr Ehlers served as chief medical officer since joining the company in September 2002. He is leaving to take up a position in academia. Dr Ehlers has agreed
Simultaneously, the company expanded its operations in China to increase MicuRx’s capacity in antibacterial drug discovery and development. To facilitate the development of its lead compounds and expand